Skip to content. | Skip to navigation

Personal tools
Log in
You are here: Home Know-who Know-how Directory From A to Z Progressare BV

Progressare BV

Business focus: Development, outsourced manufacturing, licenses of medical products between cosmetics and pharmaceutical categories. Products are registered as medical devices or combination products (medical device and pharmaceutical mode of action). Most products are OTC (over-the-counter) sold.



Progressare

Progressare BV
Veembroederhof 96
1019 HC Amsterdam
Website Progressare BV
E-mail Progressare BV
T +31 (0)20 345 95 05
F +31 (0)20 640 51 68

Employees in Amsterdam: 15
Employees in R&D: 10
Year of foundation: 2002

Company profile

Development, outsourced manufacturing, licenses of medical products between cosmetics and pharmaceutical categories. Products are regeistered as medical devices or combination products (medical device and pharmaceutical mode of action). Most products are OTC (over-the-counter) sold.

Science and Technologies or Services

Development of active ingredient with bio adhesive film layer to treat and prevent diseases. Combined with unique delivery system.

Alliances

Progressare develops and licenses products to Merck, Chefaro, Wyeth, Glaxo (Big Pharma).

Keywords

  • Medical device;
  • Active ingredients;
  • Progressare;
  • PQS;
  • Quality;
  • Regulatory;
  • Pharmaceutical;
  • 93/42/ec;
  • 2007/47/ec;
  • iso-13485;
  • ce;
  • otc.
Document Actions

Find your life sciences partner in the Amsterdam BioMed Cluster

Find your life sciences partner in the Amsterdam BioMed Cluster

Column

Penny-wise!

Synaps bij column Arjen Brussaard, foto CNCR.nl

By Arjen Brussaard

Recently the topsector plan Life Sciences & Health was published and presented to Minister Verhagen, of the so-called ELI Ministry. The document is an amazing compressed 60-pager, based on months of hard work by the group of experts chaired by Roel Fonville, and summarizes the conclusions after dozens of 1-to-1 meetings, five regional group sessions with dozens of opinion leaders and after having received over 170 (!) memo's, white papers and letters of intent.
More...